Conv. Plasma
Nigella Sativa

All vitamin D studies
Meta analysis
study COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 58% Improvement Relative Risk Vitamin D for COVID-19  Shamsi et al.  LATE TREATMENT Is late treatment with vitamin D beneficial for COVID-19? Retrospective 183 patients in Iran (March 2020 - August 2021) Study underpowered to detect differences Shamsi et al., Canadian J. Infectious .., Jul 2023 Favors vitamin D Favors control

Survival and Mortality in Hospitalized Children with COVID-19: A Referral Center Experience in Yazd, Iran

Shamsi et al., Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2023/5205188
Jul 2023  
  Source   PDF   All   Meta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
*, now known with p < 0.00000000001 from 118 studies, recognized in 7 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective 183 hospitalized pediatric COVID-19 patients in Iran, showing no significant difference in mortality with vitamin D in unadjusted results.
Cholecalciferol was used in this study. Meta analysis shows that late stage treatment with calcitriol / calcifediol (or paricalcitol, alfacalcidol, etc.) is more effective than cholecalciferol: 65% [41‑79%] lower risk vs. 39% [26‑49%] lower risk. Cholecalciferol requires two hydroxylation steps to become activated - first in the liver to calcifediol, then in the kidney to calcitriol. Calcitriol, paricalcitol, and alfacalcidol are active vitamin D analogs that do not require conversion. This allows them to have more rapid onset of action compared to cholecalciferol. The time delay for cholecalciferol to increase serum calcifediol levels can be 2-3 days, and the delay for converting calcifediol to active calcitriol can be up to 7 days.
This is the 113th of 118 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 30 sextillion). 29 studies are RCTs, which show efficacy with p=0.0000035.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
Study covers favipiravir, vitamin D, famotidine, HCQ, aspirin, and remdesivir.
risk of death, 57.5% lower, RR 0.42, p = 0.70, treatment 1 of 17 (5.9%), control 23 of 166 (13.9%), NNT 13.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shamsi et al., 17 Jul 2023, retrospective, Iran, peer-reviewed, 4 authors, study period 1 March, 2020 - 1 August, 2021, dosage not specified. Contact:
This PaperVitamin DAll
Survival and Mortality in Hospitalized Children with COVID-19: A Referral Center Experience in Yazd, Iran
Farimah Shamsi, Mehran Karimi, Zahra Nafei, Elahe Akbarian
Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2023/5205188
Introduction. COVID-19 prognostic risk factors, therapeutic protocols, and clinical outcomes in pediatric cases are still under investigation. Materials and Methods. Tis historical cohort study evaluated the survival time of hospitalized children (1 month-18 years old) with COVID-19 admitted from March 2020 to August 2021 to an educational hospital in Yazd, Iran. Te follow-up of patients was performed at least one month after discharge. Results. From 183 hospitalized cases, 24 children were deceased. Te median age of patients was 5.41, and 54.2% were male. Te survival rate after one-month follow-up was 0.88, and the most signifcant predictors associated with survival time were the male sex, positive history of hospitalization, lymphopenia, hypoxia, and length of stay more than two weeks using Bayesian Cox regression analysis. Conclusion. Accurate estimation of the impact of predictors on poor outcomes may help healthcare providers use therapeutic protocols based on risk factors and healthcare requirements of each patient to improve their survival.
Conflicts of Interest Te authors declare that they have no conficts of interest.
Armin, Fahimzad, Tabatabaei, COVID-19 mortality in children: a referral center experience from Iran (mofd children's hospital, tehran, Iran), Te Canadian Journal of Infectious Diseases and Medical Microbiology
Baumgart, Danese, Peyrin-Biroulet, Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention, and management, Clinical Gastroenterology and Hepatology
Bialek, Coronavirus disease
Buonsenso, Di Giuda, Sigfrid, Evidence of lung perfusion defects and ongoing infammation in an adolescent with post-acute sequelae of SARS-CoV-2 infection, Te Lancet Child & Adolescent Health
Buonsenso, Munblit, Rose, Preliminary evidence on long COVID in children, Acta Paediatrica
Burke, Killerby, Newton, Symptom profles of a convenience sample of patients with COVID-19-United States, MMWR. Morbidity and Mortality Weekly Report
Chang, Wu, Chang, Clinical characteristics and diagnostic challenges of pediatric COVID-19: a systematic review and meta-analysis, Journal of the Formosan Medical Association
Dong, Mo, Hu, Epidemiology of COVID-19 among children in China, Pediatrics
Gallo Marin, Aghagoli, Lavine, Predictors of COVID-19 severity: a literature review, Reviews in Medical Virology
Garg, Kim, Whitaker, Hospitalization rates and characteristics of patients hospitalized with laboratory-10 Canadian Journal of Infectious Diseases and Medical Microbiology confrmed coronavirus disease
Götzinger, Santiago-García, Noguera-Julián, COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study, Te Lancet Child & Adolescent Health
Jutzeler, Bourguignon, Weis, Comorbidities, clinical signs and symptoms, laboratory fndings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: a systematic review and meta-analysis, Travel Medicine and Infectious Disease
Kim, Whitaker, O'halloran, Hospitalization rates and characteristics of children aged< 18 years hospitalized with laboratory-confrmed COVID-19-COVID-NET, 14 states, MMWR. Morbidity and Mortality Weekly Report
Kirby, New variant of SARS-CoV-2 in UK causes surge of COVID-19, Te Lancet Respiratory Medicine
Kompaniyets, Agathis, Nelson, Underlying medical conditions associated with severe COVID-19 illness among children, JAMA Network Open
Lee, Park, Kim, Lee, Kim, Lymphopenia as a biological predictor of outcomes in COVID-19 patients: a nationwide cohort study, Cancers
Li, Xu, Yu, Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan, Journal of Allergy and Clinical Immunology
Liu, Lei, Xiao, Epidemiological and clinical characteristics of patients with coronavirus disease-2019 in Shiyan City, China, Frontiers in Cellular and Infection Microbiology
Ludvigsson, Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults, Acta Paediatrica
Madani, Shahin, Yoosef, Red fags of poor prognosis in pediatric cases of COVID-19: the frst 6610 hospitalized children in Iran, BMC Pediatrics
Mahase, Covid-19: What New Variants Are Emerging and How Are Tey Being Investigated? 2021, British Medical Journal Publishing Group
Mahmoudi, Mehdizadeh, Badv, Te coronavirus disease 2019 (COVID-19) in children: a study in an Iranian children's referral hospital, Infection and Drug Resistance
Mamishi, Movahedi, Mohammadi, Multisystem infammatory syndrome associated with SARS-CoV-2 infection in 45 children: a frst report from Iran, Epidemiology and Infection
Mansourian, Ghandi, Habibi, Mehrabi, COVID-19 infection in children: a systematic review and meta-analysis of clinical features and laboratory fndings, Archives de Pediatrie
Martin, Dewitt, Russell, Characteristics, outcomes, and severity risk factors associated with SARS-CoV-2 infection among children in the US national COVID cohort collaborative, JAMA Network Open
Nguyen, Tuc, Hung, Risk factors for disease severity and mortality of children with Covid-19: a study at a Vietnamese Children's hospital, Journal of Infection and Chemotherapy
Oliveira, Colosimo, Simões E Silva, Clinical characteristics and risk factors for death among hospitalised children and adolescents with COVID-19 in Brazil: an analysis of a nationwide database, Te Lancet Child and Adolescent Health
Saeed, Gaba, Shah, Correlation between chest CT severity scores and the clinical parameters of adult patients with COVID-19 pneumonia, Radiology research and practice
States, MMWR, Morbidity and Mortality Weekly Report
Swann, Clinical Characteristics of Children and Young People Admitted to Hospital with Covid-19 in United Kingdom: Prospective Multicentre Observational Cohort Study, British Medical Journal Publishing Group
Von Elm, Altman, Egger, Pocock, Gøtzsche et al., Te Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, Preventive Medicine
Wang, Zheng, Zheng, Sun, Attaching clinical signifcance to COVID-19-associated diarrhea, Life Sciences
Woodruf, Risk factors for severe COVID-19 in children, Pediatrics
Worldometers, Iran COVID-Coronavirus Statistics-Worldometer
Zachariah, Johnson, Halabi, Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children's hospital in New York City, JAMA Pediatrics
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop